Succimer: Difference between revisions
(Links. Information of pharmacology) |
(Lactation) |
||
| Line 13: | Line 13: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Avoid breastfeeding during treatment and for at least 5 days after d/c. Possible risk of infant toxicity | ||
*Renal dosing: administer with caution, ensure adequate hydration | *Renal dosing: administer with caution, ensure adequate hydration | ||
*Hepatic dosing: no adjustment, monitor LFTs closely | *Hepatic dosing: no adjustment, monitor LFTs closely | ||
Revision as of 21:34, 8 September 2018
Administration
- Type: Antidote
- Dosage Forms: Capsule 100mg
- Routes of Administration: Oral
- Common Trade Names: Chemet
Adult Dosing
Lead poisoning
- 10 to 30 mg/kg/day for 5 days
Pediatric Dosing
Safety/efficacy not established in patients <12mo
- Lead poisoning, level >45 mcg/dL: 10 mg/kg or 350 mg/m(2) q8h for 5 days, then q12 h for 14 days
Special Populations
- Pregnancy Rating: C
- Lactation risk: Avoid breastfeeding during treatment and for at least 5 days after d/c. Possible risk of infant toxicity
- Renal dosing: administer with caution, ensure adequate hydration
- Hepatic dosing: no adjustment, monitor LFTs closely
Contraindications
- Allergy to class/drug
- Breastfeeding during treatment and five days after d/c
- ANC < 1200
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 48h
- Metabolism: Site unknown
- Excretion: Renal 25%, feces 39%, lungs 1%
Mechanism of Action
- Forms stable, water-soluble complexes with lead, leading to increased urinary excretion